ST. VINCENTS MEDICAL CENTER
1. Target Overview & Investment Thesis
ST. VINCENTS MEDICAL CENTER is a 211-bed suburban community hospital in FAIRFIELD, CT with $481.3M in net patient revenue and a -12.7% operating margin. The hospital serves a payer mix of 25.7% Medicare, 23.6% Medicaid, and 50.7% commercial.
Thesis: Undervalued. Our ML models identify $35.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -12.7% to -5.3% (+736bps).
| Net Revenue HCRIS | $481.3M |
| Current EBITDA COMPUTED | $-61.2M |
| Operating Margin COMPUTED | -12.7% |
| Occupancy HCRIS | 82.8% |
| Revenue / Bed COMPUTED | $2.3M |
| Net-to-Gross HCRIS | 28.6% |
| Distress Probability ML | 44.0% |
2. Market Context & Competitive Position
CT has 39 Medicare-certified hospitals with a median operating margin of -6.8%. The target's margin of -12.7% places it below the state median. Among 20 size-comparable peers (106-422 beds), the median margin is -5.8%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (106-422), prioritizing same-state peers. 20 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| ST. VINCENTS MEDICAL CENTER (Target) | CT | 211 | $481.3M | -12.7% |
| SAINT FRANCIS HOSPITAL | CT | 394 | $877.6M | -4.0% |
| THE STAMFORD HOSPITAL | CT | 288 | $786.2M | -5.1% |
| BRIDGEPORT HOSPITAL | CT | 387 | $744.6M | -12.5% |
| DANBURY HOSPITAL | CT | 338 | $714.8M | -2.9% |
| JOHN DEMPSEY HOSPITAL | CT | 141 | $590.3M | -24.8% |
| THE HOSPITAL OF CENTRAL CONNEC | CT | 244 | $541.8M | -5.6% |
| GREENWICH HOSPITAL | CT | 186 | $498.0M | -5.9% |
| MIDDLESEX HOSPITAL | CT | 186 | $449.7M | -1.3% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $35.4M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $10.1M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $9.6M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $9.5M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $5.9M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $308K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-61.2M |
| + RCM Uplift | +$35.4M |
| Pro Forma EBITDA | $-25.7M |
| Current Margin | -12.7% |
| Pro Forma Margin | -5.3% |
| WC Released (1x) | $18.5M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-94.1M | $-49.2M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-94.1M | $-84.7M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-84.7M | $1.6M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-84.7M | $-23.2M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-103.5M | $-195.8M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-103.5M | $-249.0M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
| Medium | Elevated Medicaid exposure (23.6%) | Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 20 hospitals with 106-422 beds
- Same-state prioritization (n=21)
- Comp margins: P25=-6.8% / P50=-5.8% / P75=-3.5%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.